Artificial intelligence, drug repurposing and peer review

Nat Biotechnol. 2020 Oct;38(10):1127-1131. doi: 10.1038/s41587-020-0686-x.

Jeremy M Levin^{1

2}, Tudor I Oprea^{3

4

5

6}, Sagie Davidovich⁷, Thomas Clozel⁸, John P Overington⁹, Quentin Vanhaelen¹⁰, Charles R Cantor¹¹, Evelyne Bischof^#^{12

13

14}, Alex Zhavoronkov^#¹⁵

¹ Ovid Therapeutics, Inc, New York, NY, USA.
² Biotechnology Innovation Organization (BIO), Washington, DC, USA.
³ Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
⁴ Autophagy Inflammation and Metabolism Center of Biomedical Research Excellence, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
⁵ Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
⁶ Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁷ SparkBeyond, Netanya, Israel.
⁸ Owkin, Paris, France.
⁹ Medicines Discovery Catapult, Cheshire, UK.
¹⁰ Insilico Medicine, Hong Kong Science and Technology Park, Hong Kong, China.
¹¹ Retrotope, Inc, Los Altos, CA, USA.
¹² Insilico Medicine, Hong Kong Science and Technology Park, Hong Kong, China. bischofevelyne@gmail.com.
¹³ Shanghai University of Medicine and Health Sciences, College of Clinical Medicine, Shanghai, China. bischofevelyne@gmail.com.
¹⁴ Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. bischofevelyne@gmail.com.
¹⁵ Insilico Medicine, Hong Kong Science and Technology Park, Hong Kong, China. alex@insilico.com.

^# Contributed equally.

No abstract available

Publication types